Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 9/20 | 0.74 |
| ▸ | LOX | P28300 | 4/20 | 0.74 |
| ▸ | IKBKE | Q14164 | 3/20 | 0.50 |
| ▸ | TBK1 | Q9UHD2 | 3/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.41 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.40 |
| ▸ | ACACB | O00763 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4935204 | 0.92 | LOXL2 (0.66) | LOXL2LOXIKBKETBK1HDAC6 | |
| SCHEMBL25260001 | 0.86 | LOXL2 (0.91) | LOXL2LOXIKBKETBK1CSNK2A1 | |
| SCHEMBL2600007 | 0.86 | LOXL2 (0.97) | LOXL2LOXIKBKETBK1CSNK2A1 | |
| SCHEMBL16220848 | 0.85 | LOX (0.54) | LOXL2LOXIKBKETBK1HDAC6 | |
| SCHEMBL25207220 | 0.85 | LOXL2 (0.68) | LOXL2LOXIKBKETBK1LOXL3 | |
| SCHEMBL18049156 | 0.85 | LOXL2 (1.00) | LOXL2LOXIKBKETBK1CSNK2A1 | |
| SCHEMBL4935143 | 0.81 | LOXL2 (0.52) | LOXL2LOXIKBKETBK1LOXL3 | |
| SCHEMBL30939176 | 0.81 | LOXL2 (0.52) | LOXL2LOXIKBKETBK1LOXL3 | |
| SCHEMBL3401548 | 0.80 | HDAC6 (0.50) | LOXL2LOXHDAC6LRRK2ACACB | |
| SCHEMBL445290 | 0.80 | LOXL2 (0.70) | LOXL2LOXIKBKETBK1LOXL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4452944-A1 | CYCLOPROPYL COMPOUNDS | Icagen, LLC (US) | 2024-10-30 | — | — | EP | disclosed |
| US-20240336571-A1 | NOVEL CYCLOPROPYL COMPOUNDS | ANGELINI PHARMA S.P.A. (IT) | 2024-10-10 | — | — | US | disclosed |
| WO-2023121992-A1 | CYCLOPROPYL COMPOUNDS | ICAGEN, LLC (US) | 2023-06-29 | — | — | WO | disclosed |
| US-9475822-B2 | Substituted 2- amidoquinazol-4-ones as matrix metalloproteinase-13 inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-10-25 | — | — | US | disclosed |
| US-9212149-B2 | Substituted 2-amidoquinazol-4-ones as matrix metalloproteinase-13 inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-12-15 | — | — | US | disclosed |
| US-20150329556-A1 | SUBSTITUTED 2- AMIDOQUINAZOL-4-ONES AS MATRIX METALLOPROTEINASE-13 INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2015-11-19 | — | — | US | disclosed |
| EP-1740551-B9 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF AS AN MMP-13 INHIBITOR | TAKEDA PHARMACEUTICAL (JP) | 2013-01-16 | — | — | EP | disclosed |
| EP-1740551-B1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF AS AN MMP-13 INHIBITOR | TAKEDA PHARMACEUTICAL (JP) | 2012-09-12 | — | — | EP | disclosed |
| US-20080027050-A1 | Heterocyclic Amide Compound and Use Thereof as an Mmp-13 Inhibitor(Amended Ex Officio) | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329556-A1 | SUBSTITUTED 2- AMIDOQUINAZOL-4-ONES AS MATRIX METALLOPROTEINASE-13 INHIBITORS | MMP13, MMP14, MMP25 | LOXL2 2869/4885LOX 2210/4885IKBKE 652/4885 |
| US-20080027050-A1 | Heterocyclic Amide Compound and Use Thereof as an Mmp-13 Inhibitor(Amended Ex Officio) | MMP13, HDAC11, HDAC1 | LOXL2 3474/4885LOX 1715/4885IKBKE 1176/4885 |
| US-20240336571-A1 | NOVEL CYCLOPROPYL COMPOUNDS | C1R, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CNR1 | LOXL2 4525/4885LOX 4419/4885IKBKE 528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.